Sidley advised Pivotal bioVenture Partners China (Pivotal), a leading venture capital fund in the field of life sciences, and Frazier Healthcare Partners (Frazier), a leading provider of growth and venture capital to healthcare companies, in the formation of SanReno Therapeutics (SanReno), a joint venture with Chinook Therapeutics, Inc. (Nasdaq: KDNY) (Chinook), a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, and the equity investment in SanReno.
SanReno is a joint venture with an investor syndicate led by Pivotal and Frazier, along with existing Chinook investors, to develop, manufacture, and commercialize kidney disease therapies in Greater China and Singapore. Chinook has granted SanReno exclusive rights to develop, manufacture, and commercialize Atrasentan and BION-1301 in Greater China and Singapore.
The Sidley team was led by partners Ruchun Ji and Josh Hofheimer; other team members included senior associate Eric Cheng and associates Longbo Wang, Jean Qiu, Rui Liu, and Xiaolin Zhu.
Sidley provides multidisciplinary services for life sciences clients. We advise clients across the full spectrum of their business lifecycles, ranging from formation, corporate governance, and compliance operations for start-ups, to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offerings, equity financings, and bond/note issuances, as well as domestic and cross-border mergers and acquisitions, asset restructuring, equity incentive plans, and privatizations.